Moneycontrol PRO

business

Sun Pharma a must in core portfolio: Experts

Market experts Nipun Mehta and Dilip Bhatdo see no negatives for Sun Pharma if the Ranbaxy deal goes through.

first published: Nov 11, 2014 03:38 pm

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347